What kind of medicine is Laos Element Pharmaceuticals Sotolasibu?

Sotoracib (AMG510) is an inhibitor of the RAS GTP enzyme family and is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). ), received at least one prior systemic therapy as determined by FDA-approved testing. Sotoracib is the first targeted drug targeting the KRAS G12C- mutation and has a remarkable therapeutic effect.

The recommended dose of sotoraxib is 960 mg taken orally once daily. Monitor liver function tests every 3 weeks for the first 3 months of treatment and then monthly as clinically indicated and suspend, reduce dose, or permanently discontinue sotoraxib based on severity. Monitor for new or worsening pulmonary symptoms and discontinue sotoraxib immediately for suspectedILD/pneumonitis or permanently if no other potential cause ofILD/pneumonitis is identified. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed duringsotoraxibtreatment and for1weeks after the last dose.

The most common adverse reactions (≥ 20%) with sotorasiib were diarrhea, musculoskeletal pain, nausea, fatigue, hepatotoxicity, and cough. The most common laboratory abnormalities(≥ 25%)are lymphopenia, decreased hemoglobin, increased aspartate aminotransferase, increased alanine aminotransferase, decreased calcium, increased alkaline phosphatase, increased urinary protein, and decreased sodium. Laos Element Pharmaceuticals Retail price120mg56 tablets sell for more than 2 more than one thousand. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.

xa0